Exploratory analysis of serum and pleural effusion biomarkers in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion

Exploratory analysis of serum and pleural effusion biomarkers in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion - Exploratory analysis of serum and pleural effusion biomarkers in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006768

Enrollment

Registered

2011-11-30

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous non-small-cell lung cancer

Interventions

Carboplatin + Paclitaxel + Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who registered phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion. 2. Patients treated at division of thoracic oncology, Shizuoka Cancer Center. 3. All subjects must be able to provide informed,written consent prio to entry.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Exploring several predictable biomarkers	—

Countries

Japan

Contacts

Public ContactMadoka Kimura

Shizuoka Cancer Cetner Division of Thoracic Oncology

055-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026